Heparin-related nanomaterials

Heparin: Properties, Uses and Side Effects

Volumn , Issue , 2012, Pages 159-178

  Gu, Zi ^a   Rolfe, Barbara E ^a   Thomas, Anita C ^b   Campbell, Julie H ^a   Lu, G Q ^a   Xu, Zhi Ping ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84887899303     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Capila I, Linhardt RJ. Heparin -Protein interactions. Angew Chem-Int Edit 2002;41(3):391-412.
2. Pineo GF, Hull RD. Unfractionated and low-molecular-weight heparin -Comparisons and current recommendations. Med Clin N Am 1998;82(3):587-99.
3. Wang Y, Xin DC, Liu KJ, Zhu MQ, Xiang JN. Heparin-Paclitaxel Conjugates as Drug Delivery System: Synthesis, Self-Assembly Property, Drug Release, and Antitumor Activity. Bioconjugate Chem 2009;20(12):2214-21.
4. Hartmann LC, Keeney GL, Lingle WL, Christianson TJH, Varghese B, Hillman D, et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer 2007;121(5):938-42.
5. Iwakiri S, Sonobe M, Nagai S, Hirata T, Wada H, Miyahara R. Expression status of folate receptor alpha is significantly correlated with prognosis in non-small-cell lung cancers. Ann Surg Oncol 2008;15(3):889-99.
6. Kalli KR, Oberg AL, Keeney GL, Christianson TJH, Low PS, Knutson KL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008;108(3):619-26.
7. Wang Y, Wang YQ, Xiang JN, Yao KT. Target-Specific Cellular Uptake of Taxol-Loaded Heparin-PEG-Folate Nanoparticles. Biomacromolecules 2010;11(12):3531-8.
8. Wang X, Li J, Wang YQ, Cho KJ, Kim G, Gjyrezi A, et al. HFT-T, a Targeting Nanoparticle, Enhances Specific Delivery of Paclitaxel to Folate Receptor-Positive Tumors. ACS Nano 2009;3(10):3165-74.
9. Li L, Huh KM, Lee YK, Kim SY. Design of a Multifunctional Heparin-based Nanoparticle System for Anticancer Drug Delivery. Macromol Res 2010;18(2):153-61.
10. Bae KH, Mok H, Park TG. Synthesis, characterization, and intracellular delivery of reducible heparin nanogels for apoptotic cell death. Biomaterials 2008;29(23):3376-83.
11. Park K, Kim K, Kwon IC, Kim SK, Lee S, Lee DY, et al. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir 2004;20(26):11726-31.
12. Park K, Lee GY, Kim YS, Yu M, Park RW, Kim IS, et al. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release 2006;114(3):300-6.
13. Chauvierre C, Marden MC, Vauthier C, Labarre D, Couvreur P, Leclerc L. Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrier. Biomaterials 2004;25(15):3081-6.
14. Fontana G, Licciardi M, Mansueto S, Schillaci D, Giammona G. Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake. Biomaterials 2001;22(21):2857-65.
15. Moghimi SM, Patel HM. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system -The concept of tissue specificity. Adv Drug Deliv Rev 1998;32(1-2):45-60.
16. Wuang SC, Neoh KG, Kang ET, Pack DW, Leckband DE. Heparinized magnetic nanoparticles: In-vitro assessment for biomedical applications. Adv Funct Mater 2006;16(13):1723-30.
17. McKay EJ, Laurell CB. The interaction of heparin with plasma proteins. Demonstration of different binding sites for antithrombin III complexes and antithrombin III. J Lab Clin Med 1980;95(1):69-80.
18. Chauvierre C, Labarre D, Couvreur P, Vauthier C. Novel polysaccharide-decorated poly(isobutyl cyanoacrylate) nanoparticles. Pharm Res 2003;20(11):1786-93.
19. Han HD, Lee A, Song CK, Hwang T, Seong H, Lee CO, et al. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm 2006;313(1-2):181-8.
20. Hiebert LM, Jaques LB. The observation of heparin on endothelium after injection. Thromb Res 1976;8(2):195-204.
21. Damus PS, Hicks M, Rosenber.Rd. Anitcoagulant action of heparin. Nature 1973;246(5432):355-7.
22. Wilson CG, Sisco PN, Goldsmith EC, Murphy CJ. Glycosaminoglycan-functionalized gold nanorods: interactions with cardiac cells and type I collagen. J Mater Chem 2009;19(35):6332-40.
23. Chung YI, Kim JC, Kim YH, Tae G, Lee SY, Kim K, et al. The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronic on tumor targeting. J Control Release 2010;143(3):374-82.
24. Zhang Q, Chen S, Zhuo RX, Zhang XZ, Cheng SX. Self-Assembled Terplexes for Targeted Gene Delivery with Improved Transfection. Bioconjugate Chem 2010;21(11):2086-92.
25. Sharma CP, Jayasree G. Surface modification of polyurethane films by liposome-encapsulated heparin. J Colloid Interface Sci 1990;137(1):289-91.
26. Koromila G, Michanetzis GPA, Missirlis YF, Antimisiaris SG. Heparin incorporating liposomes as a delivery system of heparin from PET-covered metallic stents: Effect on haemocompatibility. Biomaterials 2006;27(12):2525-33.
27. Murugesan S, Park TJ, Yang HC, Mousa S, Linhardt RJ. Blood compatible carbon nanotubes -Nano-based neoproteoglycans. Langmuir 2006;22(8):3461-3.
28. Morishita N, Nakagami H, Morishita R, Takeda S, Mishima F, Terazono B, et al. Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. Biochem Biophys Res Commun 2005;334(4):1121-6.
29. Villanueva A, Canete M, Roca AG, Calero M, Veintemillas-Verdaguer S, Serna CJ, et al. The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 2009; 20(11).
30. Risau W. Mechanisms of angiogenesis. Nature 1997;386(6626):671-4.
31. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN, et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996;94(5):1074-82.
32. Sakiyama-Elbert SE, Hubbell JA. Development of fibrin derivatives for controlled release of heparin-binding growth factors. J Control Release 2000;65(3):389-402.
33. Kweon DK, Song SB, Park YY. Preparation of water-soluble chitosan/heparin complex and its application as wound healing accelerator. Biomaterials 2003;24(9):1595-601.
34. Chung YI, Kim SK, Lee YK, Park SJ, Cho KO, Yuk SH, et al. Efficient revascularization by VEGF administration via heparin-functionalized nanoparticle-fibrin complex. J Control Release 2010;143(3):282-9.
35. Chung YI, Tae G, Yuk SH. A facile method to prepare heparin-functionalized nanoparticles for controlled release of growth factors. Biomaterials 2006;27(12):2621-6.
36. Chung YI, Ahn KM, Jeon SH, Lee SY, Lee JH, Tae G. Enhanced bone regeneration with BMP-2 loaded functional nanoparticle-hydrogel complex. J Control Release 2007;121(1-2):91-9.
37. Lee HJ, Park KH, Park SR, Min BH. Chitosan/Heparin polyelectrolyte complex nanoparticles (100 similar to 200nm) covalently bonded with PEI for enhancement of chondrogenic phenotype. In: Kim YH, Cho CS, Kang IK, Kim SY, Kwon OH, editors. ASBM7: Advanced Biomaterials VII. Stafa-Zurich: Trans Tech Publications Ltd; 2007. p. 329-32.
38. Na K, Kim S, Park K, Kim K, Woo DG, Kwon IC, et al. Heparin/poly(L-lysine) nanoparticle-coated polymeric microspheres for stem-cell therapy. J Am Chem Soc 2007;129(18):5788-+.
39. Na K, Kim SW, Sun BK, Woo DG, Chung HM, Park KH. Blended construct consisting of thermo-reversible hydrogels and heparinized nanoparticles for increasing the proliferation activity of the rabbit chondrocyte in vivo test. Biotechnol Lett 2007;29(10):1447-52.
40. Benoit DSW, Durney AR, Anseth KS. The effect of heparin-functionalized PEG hydrogels on three-dimensional human mesenchymal stem cell osteogenic differentiation. Biomaterials 2007;28(1):66-77.
41. Fu JH, Ji J, Yuan WY, Shen JC. Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. Biomaterials 2005;26(33):6684-92.
42. Yuan WY, Fu JH, Su K, Ji J. Self-assembled chitosan/heparin multilayer film as a novel template for in. Colloid Surf B-Biointerfaces 2010;76(2):549-55.
43. Viswanathan G, Murugesan S, Pushparaj V, Nalamasu O, Ajayan PM, Linhardt RJ. Preparation of biopolymer fibers by electrospinning from room temperature ionic liquids. Biomacromolecules 2006;7(2):415-8.
44. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? J Am Coll Cardiol 2000;35(7):1699-712.
45. Frydman AM, Bara L, Leroux Y, Woler M, Chauliac F, Samama MM. The antithrobotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutanenous doese of 20 to 80 mg. J Clin Pharmacol 1988;28(7):609-18.
46. Money SR, York JW. Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis. Cardiovasc Surg 2001;9(3):211-8.
47. Edelman ER, Karnovsky MJ. Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis. Circulation 1994;89(2):770-6.
48. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 1964;8(5):660-&.
49. Kim TD, Kambayashi J, Sakon M, Tsujinaka T, Ohshiro T, Mori T. Metabolism of liposome-encapsulated heparin. Thromb Res 1989;56(3):369-76.
50. Kim TD, Sakon M, Kawasaki T, Kambayashi J, Ohshiro T, Mori T. Studies on liposome-encapsulated heparin. Thromb Res 1986;43(6):603-12.
51. Bai S, Gupta V, Ahsan F. Cationic liposomes as carriers for aerosolized formulations of an anionic drug: Safety and efficacy study. Eur J Pharm Sci 2009;38(2):165-71.
52. Bai SH, Ahsan F. Inhalable Liposomes of Low Molecular Weight Heparin for the Treatment of Venous Thromboembolism. J Pharm Sci 2010;99(11):4554-64.
53. Song YK, Kim CK. Topical delivery of low-molecular-weight heparin with surface-charged flexible liposomes. Biomaterials 2006;27(2):271-80.
54. Betz G, Imboden R, Imanidis G. Interaction of liposome formulations with human skin in vitro. Int J Pharm 2001;229(1-2):117-29.
55. Betz G, Nowbakht P, Imboden R, Imanidis G. Heparin penetration into and permeation through human skin from aqueous and liposomal formulations in vitro. Int J Pharm 2001;228(1-2):147-59.
56. Gorski G, Szopinski P, Michalak J, Marianowska A, Borkowski M, Geremek M, et al. Liposomal heparin spray: A new formula in adjunctive treatment of superficial venous thrombosis. Angiology 2005;56(1):9-17.
57. Moon JW, Song YK, Jee JP, Kim CK, Choung HK, Hwang JM. Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Invest Ophthalmol Vis Sci 2006;47(9):3968-74.
58. Sun W, Mao SR, Mei D, Kissel T. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin. Eur J Pharm Biopharm 2008;69(2):417-25.
59. Chen MC, Wong HS, Lin KJ, Chen HL, Wey SP, Sonaje K, et al. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 2009;30(34):6629-37.
60. Wang HM, Loganathan D, Linhardt RJ. Determination of the pKa of glucuronic acid and the carboxy groups of heparin by carbon-13 nuclear magnetic resonance spectroscopy. Biochem J 1991;278:689-95.
61. Sun W, Mao SR, Wang YJ, Junyaprasert VB, Zhang TT, Na LD, et al. Bioadhesion and oral absorption of enoxaparin nanocomplexes. Int J Pharm 2010;386(1-2):275-81.
62. Bae K, Moon C, Lee Y, Park T. Intracellular Delivery of Heparin Complexed with Chitosan-g-Poly(Ethylene Glycol) for Inducing Apoptosis. Pharm Res 2009;26(1):93-100.
63. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int J Pharm 2009;381(2):122-9.
64. Hoffart V, Ubrich N, Simonin C, Babak V, Vigneron C, Hoffman M, et al. Low molecular weight heparin-loaded polymeric nanoparticles: Formulation, characterization, and release characteristics. Drug Dev Ind Pharm 2002;28(9):1091-9.
65. Eidi H, Joubert O, Attik G, Duval RE, Bottin MC, Hamouia A, et al. Cytotoxicity assessment of heparin nanoparticles in NR8383 macrophages. Int J Pharm 2010;396(1-2):156-65.
66. Jiao YY, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, et al. In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation 2002;105(2):230-5.
67. Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Control Release 2006;113(1):38-42.
68. Bai SH, Thomas C, Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J Pharm Sci 2007;96(8):2090-106.
69. Feng XY, Cheng YY, Yang K, Zhang JH, Wu QL, Xu TW. Host-Guest Chemistry of Dendrimer-Drug Complexes. 5. Insights into the Design of Formulations for Noninvasive Delivery of Heparin Revealed by Isothermal Titration Calorimetry and NMR SI.udies. J Phys Chem B 2010;114(34):11017-26.
70. Bai SH, Ahsan F. Synthesis and Evaluation of Pegylated Dendrimeric Nanocarrier for Pulmonary Delivery of Low Molecular Weight Heparin. Pharm Res 2009;26(3):539-48.
71. Oh JM, Park M, Kim ST, Jung JY, Kang YG, Choy JH. Efficient delivery of anticancer drug MTX through MTX-LDH nanohybrid system. J Phys Chem Solids 2006;67(5-6):1024-7.
72. Kriven WM, Kwak SY, Wallig MA, Choy JH. Bio-resorbable nanoceramics for gene and drug delivery. MRS Bull 2004;29(1):33-7.
73. Ambrogi V, Fardella G, Grandolini G, Perioli L, Tiralti MC. Intercalation compounds of hydrotalcite-like anionic clays with anti-inflammatory agents, II: uptake of diclofenac for a controlled release formulation. AAPS PharmSciTech [serial on the Internet]. 2002; 3(3).
74. Ambrogi V, Fardella G, Grandolini G, Perioli L. Intercalation compounds of hydrotalcite-like anionic clays with antiinflammatory agents -I. Intercalation and in vitro release of ibuprofen. Int J Pharm 2001;220(1-2):23-32.
75. Zhang H, Zou K, Guo SH, Duan X. Nanostructural drug-inorganic clay composites: Structure, thermal property and in vitro release of captopril-intercalated Mg-Al-layered double hydroxides. J Solid State Chem 2006;179(6):1792-801.
76. Zhang H, Pan DK, Duan X. Synthesis, Characterization, and Magnetically Controlled Release Behavior of Novel Core-Shell Structural Magnetic Ibuprofen-Intercalated LDH Nanohybrids. J Phys Chem C 2009;113(28):12140-8.
77. Tyner KM, Schiffman SR, Giannelis EP. Nanobiohybrids as delivery vehicles for camptothecin. J Control Release 2004;95(3):501-14.
78. Ferruccio Trifiro AV. Hydrotalcite-like anionic clays. In: Jerry L. Atwood JEDD, David D. Macnicol, Fritz Vogtle, editor. Comprehensive supramolecular chemistry New York: Pergamon Press; 1996. p. 251-91.
79. Braterman PS, Xu ZP, Yarberry F. Layered Double Hydroxides (LDHs). In: Auerbach SM, Carrado KA, Dutta PK, editors. Handbook of Layered Materials. New York: Marcel Dekker; 2004. p. 373-474.
80. Miyata S. Anion-exchange properties of hydrotalcite-like compounds. Clay Clay Min 1983;31(4):305-11.
81. Xu ZP, Zeng QH, Lu GQ, Yu AB. Inorganic nanoparticles as carriers for efficient cellular delivery. Chem Eng Sci 2006;61(3):1027-40.
82. Xu ZP, Lu GQ. Layered double hydroxide nanomaterials as potential cellular drug delivery agents. Pure Appl Chem 2006;78(9):1771-9.
83. Gu Z, Thomas AC, Xu ZP, Campbell JH, Lu GQ. In vitro sustained release of LMWH from MgAl-layered double hydroxide nanohybrids. Chem Mat 2008;20(11):3715-22.
84. Gu Z, Rolfe BE, Xu ZP, Thomas AC, Campbell JH, Lu GQM. Enhanced effects of low molecular weight heparin intercalated with layered double hydroxide nanoparticles on rat vascular smooth muscle cells. Biomaterials 2010;31(20):5455-62.
85. Gu Z, Rolfe BE, Thomas AC, Campbell JH, Lu GQ, Xu ZP. Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells. Biomaterials 2011;32(29):7234-40.
86. Thomas AC, Campbell JH. Conjugation of an antibody to cross-linked fibrin for targeted delivery of anti-restenotic drugs. J Control Release 2004;100(3):357-77.
87. Lee YK, Moon HT, Byun Y. Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb Res 1998;92(4):149-56.
88. Ross BP, Toth I. Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers. Curr Drug Deliv 2005;2(3):277-87.
89. Moon HT, Lee YK, Han JK, Byun Y. A novel formulation for controlled release of heparin-DOCA conjugate dispersed as nanoparticles in polyurethane film. Biomaterials 2001;22(3):281-9.
90. Kim SK, Vaishali B, Lee E, Lee S, Lee YK, Kumar TS, et al. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation. Thromb Res 2006;117(4):419-27.
91. Salartash K, Gonze MD, Leone-Bay A, Baughman R, Sternbergh WC, Money SR. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. J Vasc Surg 1999;30(3):526-31.
92. Gonze MD, Manord JD, Leone-Bay A, Baughman RA, Garrard CL, Sternbergh WC, et al. Orally administered heparin for preventing deep venous thrombosis. Am J Surg 1998;176(2):176-8.
93. Gonze MD, Salartash K, Sternbergh WC, Baughman RA, Leone-Bay A, Money SR. Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. Circulation 2000;101(22):2658-61.
94. Thomas AC, Campbell JH. Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis. Atherosclerosis 2004;176(1):73-81.
95. Thomas AC, Campbell JH. Timecourse of fibrin deposition and removal after arterial injury. Thromb Res 2003;109(1):65-9.
96. Linhardt RJ. 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: Structure and activity. J Med Chem 2003;46(13):2551-64.
97. Smorenburg SM, Van Noorden CJF. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001;53(1):93-105.
98. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab Invest 1985;52(6):611-6.
99. Kim YJ, Park IK, Kim JS, Hwang J, Chung ES, Huh KM, et al., editors. Anticancer Drug Delivery for Tumor Targeting and Therapy. 2009 4th IEEE International Conference on Nano/Micro Engineered and Molecular Systems, Vols 1 and 2; 2009; New York: IEEE.
100. Lv HT, Zhang SB, Wang B, Cui SH, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006;114(1):100-9.